Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Bioadaptives (BDPT) Asset Writedowns and Impairment (2024)

Bioadaptives' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $60000.0 for Q3 2024.

Quarterly results put Asset Writedowns and Impairment at $60000.0 for Q3 2024, changed N/A from a year ago — trailing twelve months through Sep 2025 was $60000.0 (changed N/A YoY), and the annual figure for FY2024 was $18000.0, changed.
Asset Writedowns and Impairment for Q3 2024 was $60000.0 at Bioadaptives.
In the past five years, Asset Writedowns and Impairment ranged from a high of $60000.0 in Q3 2024 to a low of $60000.0 in Q3 2024.